|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/7072 | (2006.01) |
| A61K 31/4745 | (2006.01) | ||
| A61K 31/506 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 43/00 | (2006.01) |
| (11) | Number of the document | 2979701 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14773672.2 |
| Date of filing the European patent application | 2014-03-27 | |
| (97) | Date of publication of the European application | 2016-02-03 |
| (45) | Date of publication and mention of the grant of the patent | 2020-08-26 |
| (46) | Date of publication of the claims translation | 2020-11-10 |
| (86) | Number | PCT/JP2014/058732 |
| Date | 2014-03-27 |
| (87) | Number | WO 2014/157443 |
| Date | 2014-10-02 |
| (30) | Number | Date | Country code |
| 2013066073 | 2013-03-27 | JP |
| (72) |
OKABE, Hiroyuki, JP
|
| (73) |
Taiho Pharmaceutical Co., Ltd.,
1-27, Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444,
JP
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Priešnavikinis agentas, įskaitant irinotekano hidrochlorido hidratą |
| ANTITUMOR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE |
| Payment date | Validity (years) | Amount | |
| 2025-02-27 | 12 | 289.00 EUR |
| 2026-03-27 |